US FDA Proposes New Medtech Fee Categories
This article was originally published in SRA
The US Food and Drug Administration is proposing to create new user fees to pay for de novo classification reviews and pre-submission consultations, among other reforms, as part of the next user fee program (MDUFA IV)1.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.